RNAi silencing of the WT1 gene inhibits cell proliferation and induces apoptosis in the B16F10 murine melanoma cell line

Melanoma Research

Volumn 17, Issue 6, 2007, Pages 341-348

  Zamora Avila, Diana E ^a   Franco Molina, Moisés A ^a   Trejo Avila, Laura M ^a   Rodríguez Padilla, Cristina ^a   Reséndez Pérez, Diana ^a   Zapata Benavides, Pablo ^a,b  

^a University Autónoma of Nuevo Leon   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

Author keywords

Apoptosis; Caspase 3; Melanoma; Poly ADP ribose polymerase; RNA interference; WT1

Indexed keywords

CASPASE 3; DNA FRAGMENT; GENE PRODUCT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; UNCLASSIFIED DRUG; WILM TUMOR PROTEIN 1;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CELL VIABILITY; CHROMATIN CONDENSATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME ACTIVATION; GENE; GENE CONSTRUCT; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA INTERFERENCE; WT1 GENE;

ANIMALS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; GENES, WILMS TUMOR; HUMANS; MELANOMA, EXPERIMENTAL; MICE; PROTEIN ISOFORMS; RNA INTERFERENCE; WT1 PROTEINS;

EID: 36048933957     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3282efd3ae     Document Type: Article

References (46)

1. Dreno B. Melanoma. Rev Prat 1999; 49:833-837.
2. Rigel DS, Friedman RJ, Kopf AW. The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J Am Acad Dermatol 1996; 34:839-847.
3. Queirolo P, Acquati M, Kirkwood JM, Eggermont AM, Rocca A, Testori A. Update: current management issues in malignant melanoma. Melanoma Res 2005; 15:319-324.
4. Brown TJ, Nelson BR. Malignant melanoma: a clinical review. Cutis 1999; 63:275-278, 281-284.
5. Eggermont AM. Randomized trials in melanoma: an update. Sur Oncol Clin N Am 2006; 15:439-451.
6. Goldstein BG, Goldstein AO. Diagnosis and management of malignant melanoma. Am Fam Physician 2001; 63:1359-1368, 1374.
7. McGee JM. Immunotherapy for malignant melanoma: a review and update. Semin Surg Oncol 1991; 7:217-220.
8. Barth A, Morton DL. The role of adjuvant therapy in melanoma management. Cancer 1995; 75:726-734.
9. Kuhn CA, Hanke CW. Current status of melanoma vaccines. Dermatol Surg 1997; 23:649-654.
10. Kadison AS, Morton DL. Immunotherapy of malignant melanoma. Surg Clin Am 2003; 83:343-370.
11. Rye PD, Stigbrand T. Interfering with cancer: a brief outline of advances in RNA interference in oncology. Tumour Biol 2004; 25:329-336.
12. Hong J, Zhao Y, Huang W. Blocking c-myc and stat3 by E. Coli expressed and enzyme digested siRNA in mouse melanoma. Biochem Biophys Res Commun 2006; 348:600-605.
13. Katagiri Y, Hozumi Y, Kondo S. Knockdown of Skp2 by siRNA inhibits melanoma cell growth in vitro and in vivo. J Dermatol Sci 2006; 42:215-224.
14. Li Q, Murphy M, Ross J, Sheehan C, Carlson JA. Skp2 and p27kip1 expression in melanocytic nevi and melanoma: and inverse relationship. J Cutan Pathol 2004; 31:633-642.
15. Chen X, Lin J, Kanekura T, Su J, Lin W, Xie H, et al. A small interfering CD147-atergeting RNA inhibited the proliferation, invasiveness, and metastatic activity o malignant melanoma. Cancer Res 2006; 66:11323-11330.
16. Edovitsky E, Alkin M, Zcharia E, Peretz T, Vlodavsky I. Heparanase gene silencing, tumor invasiveness, angiogenesis and metastasis. J Natl Cancer Inst 2004; 96:1219-1230.
17. Nakai N, Kishida T, Shin-Ya M, Imanishi J, Ueda Y, Kishimoto S, et al. Therapeutic RNA interference of malignant melanoma by electrotransfer of small interfering RNA targeting Mitf. Gene Ther 2006; (Epub ahead of print).
18. Namkoong J, Martino JJ, Chen S. From existing therapies to novel targets: a current view on melanoma. Front Biosci 2006; 11:2081-2092.
19. Hieken TJ, Ronan SG, Farolan M, Shilkaitis AL, Das Gupta TK. Molecular prognostic markers in intermediate-thickness cutaneous malignant melanoma. Cancer 1999; 85:375-382.
20. Reed JA, Albino AP. Update of diagnostic and prognostic markers in cutaneous malignant melanoma. Clin Lab Med 2000; 20:817-838.
21. Tao J, Tu YT, Huang CZ, Feng AP, Wu Q, Lian YJ, et al. Inhibiting the growth of malignant melanoma by blocking the expression of vascular endothelial growth factor using an RNA interference approach. Br J Dermatol 2005; 153:715-724.
22. Watson-Hurst K, Becker D. The role of N-cadherin, MCAM and beta3 integrin in melanoma progression, proliferation, migration and invasion. Cancer Biol Ther 2006; 5:1375-1382.
23. Wagner KD, Wagner N, Schedl A. The complex life of WT1. J Cell Sci 2003; 116:1653-1658.
24. Ellisen LW. Regulation of gene expression by WT1 in development and tumorgenesis. Int J Hematol 2002; 76:110-116.
25. Sugiyama H. Wilms' tumor gene WT1: its oncogenic function and clinical application. Int J Hematol 2001; 73:177-187.
26. Oji Y, Ogawa H, Tamaki H, Oka Y, Tsuboi A, Kim EH, et al. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 1999; 90:194-204.
27. Weisser M, Kern W, Rauhut S, Schoch C, Hiddemann W, Haferlach T, et al. Prognostic impact of RT-PCR based quantification of WT1 gene expression during MRD monitoring if acute myeloid leukemia. Leukemia 2005; 19:1416-1423.
28. Miyoshi Y, Ando A, Egawa C, Taguchi T, Tamaki Y, Tamaki H, et al. High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res 2002; 8:1167-1171.
29. Srivastava A, Fuchs B, Zhang K, Ruan M, Halder C, Mahlum E, et al. High WT1 expression is associated with very poor survival of patients with osteogenic sarcoma metastasis. Clin Cancer Res 2006; 12:4237-4243.
30. Netinatsunthorn W, Hanprasertpong J, Dechsukhum C, Leetanaporn R, Geater A. WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study. BMC Cancer 2006;6:90.
31. Rodeck U, Bossler A, Kari C, Humphreys CW, Gyorfi T, Maurer J, et al. Expression of the WT1 Wilms tumor gene by normal and malignant human melanocytes. Int J Cancer 1995; 59:78-82.
32. Menssen HD, Bertelmann E, Bartelt S, Schmidt RA, Pecher G, Schramm K, et al. Wilms' tumor gene (WT1) expression in lung cancer, colon cancer and glioblastoma cell lines compared to freshly isolated tumor specimens. J Cancer Res Clin Oncol 2000; 126:226-232.
33. Perry BN, Cohen C, Govindarajan B, Colsonis G, Arbiser J. Wilms tumor 1 expression present in most melanomas but nearly absent in nevi. Arch Dermatol 2006; 142:1031-1034.
34. Zapata P, Tuna M, Lopez BG, Tari A. Down regulation of Wilms' tumor 1 protein inhibits breast cancer proliferation. Biochem Biophys Res Commun 2002; 295:784-790.
35. Yamagami T, Sugiyama H, Inoue K, Ogawa H, Tatekawa Y, Hirata M, et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodexynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood 1996; 87:2878-2884.
36. Elmaagacli A, Koldehoff M, Peceny R, Klein-Hitpass L, Ottinger H, Beelen D, et al. WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells. Hematologica 2005; 90:326-334.
37. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci U S A 2004;101:13885-13890.
38. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994; 84:3071-3079.
39. Oji Y, Miyoshi S, Maeda H, Hayashi S, Tamaki H, Nakatsuka SI, et al. Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers. Int J Cancer 2002; 100:297-303.
40. Laux DE, Curran EM, Welshans WV, Lubahn DB, Huang TH-M. Hypermethylation of the Wilms tumor suppressor gene CpG island in human breast carcinomas. Breast Cancer Res Treatment 1999; 56:35-43.
41. Elvin P, Evans CW. Cell adhesion and experimental metastasis: a study using the B16 malignant melanoma model system. Eur J Cancer Clin Oncol 1984; 20:107-114.
42. Arguello F, Baggs RB, Frantz CAN. A murine model of experimental metastasis to bone and bone marrow. Cancer Res 1988; 48:6876-6881.
43. Gautam A, Densmore CH, Melton S, Golunski E, Waldrep C. Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis. Cancer Gene Ther 2002; 9:28-36.
44. Liu Y, Qu X, Wang P, Tian X, Luo Y, Liu S, et al. WT1 downregulation during K562 cell differentiation and apoptosis induced by bufalin. Zhonghua Xue Ye Xue Za Zhi 2002; 23:356-359.
45. Wu X, Wang Y, Pei X. Effect of WT1 antisense oligonucleotide on proliferation and apoptosis of human leukemia cells. Zhonghua Xue Ye Xue Za Zhi 1999; 20:631-633.
46. Algar EM, Khromykh T, Smith SI, Blackburn DM, Bryson GJ, Smith PJ. A WT1 antisense aligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines. Oncogene 1996; 12:1005-1014.